Does Capital BlueCross cover Wegovy?

What you need to qualify

• Age 12 and older
• BMI of 30 or higher
• BMI of 27 or higher with a weight-related condition (HTN, T2DM, dyslipidemia, OSA, MASH, and CVD)
• BMI of 23 or higher for patients of Asian descent
• BMI at or above the 95th percentile for age and sex

Qualification pathways

You can qualify through any one of these.

Documentation to bring

• BMI documentation meeting threshold (>= 30 kg/m2 for obesity, or >= 27 kg/m2 for overweight with comorbidity)
• Documentation of weight-related comorbidity if BMI 27-29.9 kg/m2
• For pediatric patients: age >= 12 years and body weight > 60 kg
• For continuation: documentation of >= 5% weight loss after 12 weeks at therapeutic dose

Approval and renewal

• To renew, the plan looks for at least 5% weight loss from the starting weight, At least 5% weight loss after 12 weeks at a therapeutic dose is required for continuation, and at least 12 weeks on therapy before the first renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

• Concomitant use with other semaglutide-containing products or any other GLP-1 receptor agonist is not recommended

Policy note: Wegovy is available as both subcutaneous injection and tablet formulations. Pediatric indication applies to patients aged 12 years and older with body weight > 60 kg. The Asian BMI threshold of >= 23 kg/m2 is noted in the clinical rationale for South Asian, Southeast Asian, and East Asian adults. Efficacy should be assessed after 12 weeks at a therapeutic dose; continuation recommended only for patients achieving >= 5% weight loss. Document also references Wegovy HD formulation for adults only.

Policy effective May 18, 2026 · verified June 5, 2026 · source: Pa policy

What you need to qualify

• Age 45 and older
• BMI of 27 or higher
• Established cardiovascular disease (CV death (established CVD), nonfatal MI, and nonfatal stroke)
• Not being used to treat type 1 diabetes

Qualification pathways

You can qualify through any one of these.

Documentation to bring

• Documentation of established cardiovascular disease (history of CV death risk, nonfatal MI, or nonfatal stroke)
• BMI documentation >= 27 kg/m2
• Age >= 45 years
• Confirmation of absence of diabetes (SELECT trial excluded patients with diabetes)

Not covered when

• Concomitant use with other semaglutide-containing products or any other GLP-1 receptor agonist is not recommended
• SELECT trial enrolled patients without diabetes; diabetes status should be confirmed absent for this indication

Policy note: Indication is to reduce risk of major adverse CV events (CV death, nonfatal MI, or nonfatal stroke) in adults with established CV disease and either obesity or overweight. The SELECT trial (NCT03574597) enrolled adults >= 45 years with BMI >= 27 kg/m2 and established CVD without diabetes. The document explicitly notes the SELECT trial population was 'without diabetes', supporting excludes_diabetes: true for this indication. Standard cardiovascular care should be ongoing.

Policy effective May 18, 2026 · verified June 5, 2026 · source: Pa policy

What you need to qualify

• Age 18 and older
• Confirmed MASH diagnosis by FIB-4, FibroScan_VCTE, liver_biopsy, MRE, and ELF_test, fibrosis stage F2 to F3
• Lab results confirming eligibility

Qualification pathways

You can qualify through any one of these.

Documentation to bring

• Diagnosis of noncirrhotic MASH (not cirrhotic)
• Fibrosis stage F2 or F3 confirmed by noninvasive testing or liver biopsy
• FIB-4 result as primary fibrosis risk assessment
• If FIB-4 is indeterminate or elevated: confirmatory ELF test and/or elastography (VCTE) result
• Liver biopsy results if NITs are discordant or alternate etiology suspected
• NAS score >= 4 with steatosis, lobular inflammation, and hepatocyte ballooning if biopsy-confirmed

Not covered when

• Cirrhotic MASH is excluded (noncirrhotic only)
• Concomitant use with other semaglutide-containing products or any other GLP-1 receptor agonist is not recommended

Policy note: FDA-approved for treatment of noncirrhotic MASH with moderate to advanced liver fibrosis (F2-F3) in adults. The clinical rationale describes a stepwise fibrosis assessment: Step 1 FIB-4 (primary), Step 2 ELF and/or elastography (VCTE) as secondary. MRE may be used when uncertainty persists. Liver biopsy is reserved for indeterminate/discordant NITs. Pivotal trial (Study 8/NCT04822181) required biopsy-confirmed MASH with F2-F3 fibrosis and NAS >= 4. No specific lookback periods for testing were stated in this document. Guidelines discourage alcohol consumption, with complete abstinence recommended in advanced fibrosis.

Policy effective May 18, 2026 · verified June 5, 2026 · source: Pa policy